Latest Lca-Vision Inc (LCAV) Headlines Shares o
Post# of 2
Shares of LCAV Up 39.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Mar 11, 11:01AM CDT
SmarTrend identified an Uptrend for LCA-Vision (NASDAQ:LCAV) on July 31st, 2013 at $3.87. In approximately 7 months, LCA-Vision has returned 39.46% as of today's recent price of $5.39.
39.5% Return Seen to Date on SmarTrend LCA-Vision Call (LCAV)
Comtex SmarTrend(R) - Tue Mar 04, 9:36AM CST
SmarTrend identified an Uptrend for LCA-Vision (NASDAQ:LCAV) on July 31st, 2013 at $3.87. In approximately 7 months, LCA-Vision has returned 39.46% as of today's recent price of $5.39.
Humana's Ratings Affirmed by A.M. Best - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 5:40PM CST
Credit rating agency A. M. Best Co. has affirmed some ratings of Humana Inc.
WellPoint, American Academy of Pediatrics Pen Deal (revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:29PM CST
Per the alliance, the American Academy of Pediatrics and WellPoint will chalk out a series that will educate physicians -- specifically designed for pediatricians -- on pediatric health issues like childhood obesity, asthma and behavioral concerns.
WellPoint, American Academy of Pediatrics Pen Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 5:00PM CST
WellPoint Inc. (WLP) has been working toward increasing awareness among the masses about child health. For this, the company has collaborated with The American Academy of Pediatrics.
Tenet Arm, University Health Pen Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 3:55PM CST
Tenet Healthcare subsidiary Conifer Health Solutions has inked a deal with University Health System.
Chemed Corp. (CHE) Surges: Why It Still Has Room to Run? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:45AM CST
Chemed Corp. has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy
Uptrend Call Working As LCA-Vision Stock Rises 41.3% (LCAV)
Comtex SmarTrend(R) - Tue Feb 25, 9:10AM CST
SmarTrend identified an Uptrend for LCA-Vision (NASDAQ:LCAV) on July 31st, 2013 at $3.87. In approximately 7 months, LCA-Vision has returned 41.27% as of today's recent price of $5.46.
Brower Piven Announces Class Action Lawsuit in Connection With Claims of Breaches of Fiduciary Duty by the Board of Directors of LCA-Vision, Inc. in Connection With the Sale of the Company to PhotoMedex, Inc. -- LCAV
GlobeNewswire - Fri Feb 21, 1:13PM CST
The securities litigation firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in Delaware state court on behalf of all common stockholders of LCA-Vision, Inc. ("LCA" or the "Company") (Nasdaq:LCAV).
INVESTOR ALERT: LEVI & KORSINSKY, LLP Notifies Investors of LCA-VISION INC. of Class Action Against Its Board of Directors in Connection With the Sale of the Company to PhotoMedex, Inc. -- LCAV
GlobeNewswire - Fri Feb 21, 12:28PM CST
Levi & Korsinsky notifies investors of LCA-Vision Inc. ("LCA" or "the Company") (Nasdaq:LCAV) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to PhotoMedex, Inc. (NasdaqHMD). A complaint was filed in Delaware state court.
INVESTOR ALERT - LCA-VISION INC.: The Law Offices of Vincent Wong Investigates the Sale of LCA-Vision Inc. to PhotoMedex, Inc. -- LCAV
Business Wire - Fri Feb 21, 12:11PM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of LCA-Vision Inc. (NasdaqGS:LCAV) ("LCA-Vision") in connection with the sale of the Company to PhotoMedex, Inc.
LCA-Vision Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 8:11PM CST
Dr. Howard Carr resigns as CEO due to family health-related reasons; Chairman Kevin Tomlinson has taken over responsibilities as CEO; Mrs. Ingrid Martin appointed CFO
Lifshitz & Miller Law Firm Announces Investigation of Cadence Pharmaceuticals, Inc., Chindex International, Inc., LCA-Vision, Inc., North Valley Bancorp and Texas Industries, Inc.
PR Newswire - Wed Feb 19, 2:48PM CST
Cadence Pharmaceuticals, Inc.
INVESTOR ALERT - LCA-VISION INC.: The Law Offices of Vincent Wong Investigates the Sale of LCA-Vision Inc. to PhotoMedex, Inc.
Business Wire - Wed Feb 19, 12:31PM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of LCA-Vision Inc. (NasdaqGS:LCAV) ("LCA-Vision") in connection with the sale of the Company to PhotoMedex, Inc.
Chemed Corp. (CHE) in Focus: Stock Moves 10.5% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:18AM CST
Chemed Corp. (CHE) was a big mover last session, as the company saw its shares rise by over 10% on the day.
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of LCA-Vision, Inc. Stockholders
Business Wire - Tue Feb 18, 4:36PM CST
Kirby McInerney LLP is investigating potential claims against the Board of Directors of LCA-Vision, Inc. ("LCA-Vision" or the "Company") (NASDAQ:LCAV) concerning the proposed acquisition of the Company by PhotoMedex, Inc. ("PhotoMedex") (NASDAQ: PHMP). Under the terms of the definitive merger agreement, LCA-Vision stockholders will receive $5.37 in cash for each share of LCA-Vision owned, valuing the transaction at approximately $106.4 million.
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of LCA-VISION INC. and Its Board of Directors In Connection With the Sale of the Company to PhotoMedex, Inc. -- LCAV
PR Newswire - Tue Feb 18, 11:42AM CST
Levi & Korsinsky commenced an investigation of the Board of Directors of LCA-Vision Inc. ("LCA" or "the Company") (NasdaqGS: LCAV) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to PhotoMedex, Inc. (NasdaqGS: PHMD).
Ryan & Maniskas, LLP Announces Investigation of LCA-Vision Inc.
PR Newswire - Tue Feb 18, 10:00AM CST
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of LCA-Vision Inc. ("LCA-Vision" or the "Company") (NASDAQ: LCAV) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to PhotoMedex, Inc. in a transaction valued at approximately $106.4 million.
42.8% Return Seen to Date on SmarTrend LCA-Vision Call (LCAV)
Comtex SmarTrend(R) - Tue Feb 18, 9:26AM CST
SmarTrend identified an Uptrend for LCA-Vision (NASDAQ:LCAV) on July 31st, 2013 at $3.87. In approximately 7 months, LCA-Vision has returned 42.82% as of today's recent price of $5.52.
Will LCA-Vision (LCAV) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 6:30AM CST
Will LCA-Vision (LCAV) Continue to Surge Higher?